Swelling

Dermal Fillers Market Size to Hit USD 8.8 Billion by 2035 | Exclusive Report by Roots Analysis

Retrieved on: 
Thursday, January 11, 2024
Artificial intelligence, Swelling, Dermatology, Research, Hospital, Bruise, Face, Partnership, MENA, Risk, Skin, Filler (linguistics), Allergan, Muscle weakness, Virtual reality, Ageing, Growth, Beauty salon

LONDON, Jan. 11, 2024 /PRNewswire/ -- The global dermal fillers market is estimated to be worth USD 3.1 billion in 2023 and is anticipated to reach USD 8.8 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 9.18% during the forecast period from 2023 to 2035.

Key Points: 
  • Though the dermal fillers market is expanding positively across the globe, several restraints may impact the growth.
  • The dermal fillers market is witnessing several collaborations between key players to enhance the development of advanced dermal filler formulations.
  • Based on gender, the dermal fillers market is led by females, capturing 90% of the market share in 2023.
  • The dermal fillers market report also includes detailed profiles of key players (listed below) that provide innovative vial solutions.

Dermal Fillers Market Size to Hit USD 8.8 Billion by 2035 | Exclusive Report by Roots Analysis

Retrieved on: 
Thursday, January 11, 2024
Artificial intelligence, Swelling, Dermatology, Research, Hospital, Bruise, Face, Partnership, MENA, Risk, Skin, Filler (linguistics), Allergan, Muscle weakness, Virtual reality, Ageing, Growth, Beauty salon

LONDON, Jan. 11, 2024 /PRNewswire/ -- The global dermal fillers market is estimated to be worth USD 3.1 billion in 2023 and is anticipated to reach USD 8.8 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 9.18% during the forecast period from 2023 to 2035.

Key Points: 
  • Though the dermal fillers market is expanding positively across the globe, several restraints may impact the growth.
  • The dermal fillers market is witnessing several collaborations between key players to enhance the development of advanced dermal filler formulations.
  • Based on gender, the dermal fillers market is led by females, capturing 90% of the market share in 2023.
  • The dermal fillers market report also includes detailed profiles of key players (listed below) that provide innovative vial solutions.

Elevating Veterinary Care: Walkin' Pets Launches Vet Exclusive Line at VMX 2024, Experience Live Demonstrations and Exclusive Offers at Booth #2131

Retrieved on: 
Wednesday, January 10, 2024
Swelling, Patient, Leg, VMX, Gait, Injury, Pet, DBE, Articulation (music), Orange County Convention Center, Proprioception, Movement, Bandage, DVM, Walkin, Motion, Hock, Veterinary medicine

ORLANDO, Fla., Jan. 10, 2024 /PRNewswire/ -- Walkin' Pets announces a new vet exclusive product line with mobility solutions designed for pet professionals.

Key Points: 
  • ORLANDO, Fla., Jan. 10, 2024 /PRNewswire/ -- Walkin' Pets announces a new vet exclusive product line with mobility solutions designed for pet professionals.
  • The Walkin' Pets new veterinary exclusive line gives veterinary professionals the tools they need to offer their patients the highest level of care with Walkin' Pets most advanced and trusted products designed specifically to complement their patients' treatment plans.
  • Join Walkin' Pets at VMX 2024 Booth #2131 for live demonstrations, expert consultations, and exclusive offers that underscore the brand's commitment to transforming the lives of pets and their families.
  • For more information about Walkin' Pets' Vet Exclusive Line, visit https://vets.handicappedpets.com/ or experience Walkin' Pets firsthand at VMX Booth #2131.

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Lithium, UGT, Risk, Digoxin, Shanda, Hypotension, FDA, SGLT1, Type 2 diabetes, Acute kidney injury, Congress, Pyelonephritis, Conference, Fever, Ketoacidosis, Pregabalin, Pregnancy, Pain, Assessment, Gabapentin, Tenderness, New Drug Application, Amber Grid, HCM, Common, SGLT2, PROGRESS, Hypertrophic cardiomyopathy, Diabetes, Kidney, Heart failure, Dialysis, History, Patient, Prescription, Type, Neuropathic pain, Webcast, Insulin, T2DM, EGFR, Erythema, T1DM, Hypoglycemia, Partnership, Contraindication, Diarrhea, NDA, Incidence, Swelling, Urinary tract infection, Hospital, Chronic kidney disease, Internationalized domain name, Metabolic acidosis, Creatinine, Growth, Lactation, Pharmaceutical industry

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, INN, Axial spondyloarthritis, Tissue, Heart, Cancer, Inflammation, Red, Ankylosing spondylitis, Infection, Back pain, Anatomy, Ulcer, IIA, Skin, Hidradenitis suppurativa, Tuberculosis, Bone marrow, ATC, Joint, Hidradenitis, Pain, Psoriatic arthritis, Bleeding, Disease, Nose, Blood, Safety, Heart failure, Rheumatoid arthritis, Patient, Medical Subject Headings, Pediatrics, Immune system, Ulcerative colitis, International, HS, Lupus, Arthritis, Language, Mouth, Laboratory, Scar, Child, Select, Methotrexate, TNF, Axial, Headache, Swelling, Stevens–Johnson syndrome, European Medicines Agency, Spine, Abscess, Rash, Frankincense

Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Libmyris, adalimumab, Date of authorisation: 12/11/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
Marketing, Hypothyroidism, INN, Woman, Progression-free survival, Nausea, Syndrome, Heart, Cancer, Inflammation, Skull, Proteinuria, Anatomy, Cell division, IIA, Diarrhea, Fatigue, ATC, Capsule, Bleeding, Pancreas, RET, VEGF, FGFR, Cerebral edema, Neoplasm, Stroke, Enzyme, Liver failure, Safety, Kidney cancer, Arthralgia, Heart failure, Patient, Urine, Medical Subject Headings, Stomatitis, Immune system, Everolimus, International, Encephalopathy, Language, Somatic symptom disorder, Blood, Mouth, Catherine Disher, Select, Medicine, Vomiting, Pembrolizumab, Cholesterol, PDGF, Kidney failure, Weight loss, Headache, KIT, Brain, Acral lentiginous melanoma, Swelling, Hypoesthesia, Splenic infarction, Confusion, European Medicines Agency, RCC, Kidney, Growth, Sunitinib, Hypercholesterolemia, Rash, Medical device

Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Date of authorisation: 25/08/2016, Revision: 21, Status: Authorised

OnQuality Announces FDA Clearance of IND Application for OQL025 for the treatment of EGFR Inhibitor-Induced Acneiform Rash

Retrieved on: 
Thursday, January 4, 2024
Quality of life, Food, Infection, IND, FDA, Lung, EGFR, Rash, MD, Doctor of Philosophy, Swelling, Blister, Cancer, Toxicity, Face, CARE, Patient, Neck, FACP, Pharmaceutical industry

Treatment often leads to acneiform rash, which manifests mainly on the face, neck, upper chest, and upper back.

Key Points: 
  • Treatment often leads to acneiform rash, which manifests mainly on the face, neck, upper chest, and upper back.
  • Acneiform rash is characterized by redness, swelling, itchingness, and even blistering or infection on the face, neck, upper chest, and upper back.
  • OQL025 is a first-in-disease topical agent to treat moderate to severe acneiform rash in patients receiving EGFR inhibitors.
  • OQL025 works by selectively targeting the key pathways that lead to EGFR inhibitor-induced rash.

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Floater, Cataract, Marketing, Protein, BRVO, INN, Neovascularization, Complication, ATC, DME, Endophthalmitis, Retinal detachment, Blood, Bleeding, International, Ranibizumab, AMD, Injection, Disease, Diabetes, Language, CRVO, Eye, Pressure, Swelling, Inflammation, Intraocular pressure, RVO, European Medicines Agency, Infection, Cerebral edema, CNV, Growth, Select, Macular edema, Patient, Safety, Anatomy, Paratriathlon, Retina, IIA, Retinal haemorrhage, Three-body problem, Medical device

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Chills, Patient, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Fever, Fatigue, Shingles, Human, ATC, Antibody, Bone marrow, Pain, Chronic pain, International, Injection, Headache, Disease, Ageing, Nausea, Language, HZ, Vaccination, Swelling, Red, PHN, Trigeminal neuralgia, European Medicines Agency, Chickenpox, Myalgia, Select, Anatomy, Vomiting, IIA, Vaccine

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Marketing, INN, Constipation, Leukopenia, Risk, Woman, Tremor, Nausea, Cancer, Infection, Back pain, Anatomy, Cough, IIA, Chills, Diarrhea, Fever, ATC, Insomnia, Bone marrow, Pain, Disease, Philadelphia chromosome, Edema, Neutrophil, Human, Safety, ALL, Water, Anemia, Tumor lysis syndrome, Leukemia, Blood pressure, Patient, Medical Subject Headings, Febrile neutropenia, Agency, MRD, Antibody, Cytokine release syndrome, International, Neutropenia, Blood, Language, Dizziness, Thrombocytopenia, Nervous system, Select, Vomiting, CD3, Acute leukemia, Headache, Swelling, Hypoesthesia, Confusion, European Medicines Agency, Cell, CD19, Paresthesia, Rash, Medical device

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 19, Status: Authorised